Article
PARP Inhibitors in Prostate Cancer.
Current treatment options in oncology - 1 Jun 2017
Ramakrishnan Geethakumari Praveen, Schiewer Matthew J, Knudsen Karen E, Kelly Wm Kevin
Abstract excerpt
OPINION STATEMENT: The genomic landscape of metastatic prostate cancer (mPCa) reveals that up to 90% of patients harbor actionable mutations and >20% have somatic DNA repair gene defects (DRD). This provides the therapeutic rationale of PARP inhibition (PARPi) to achieve "synthetic lethality" in treating this fatal disease. Clinical trials with PARP inhibitors have shown significant response rates up to 88% for...
Topics
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
- Biomarkers, Tumor
- Clinical Trials as Topic
- Combined Modality Therapy
- DNA Repair
- Disease Management
- Drug Resistance, Neoplasm
- Gene Expression Regulation, Neoplastic
- Humans